Imugene Launches Phase II Trial for PD1-Vaxx in Colorectal Cancer

Imugene Limited ( (AU:IMU) ) has issued an update.

Imugene Limited has announced the activation of the first site in Australia for its Phase II Neo-POLEM clinical trial, which investigates the PD1-Vaxx vaccine’s potential to improve treatment outcomes for patients with a specific subtype of colorectal cancer. This trial, conducted in collaboration with Cancer Research UK and other partners, aims to determine the vaccine’s effectiveness in reducing tumor size and improving survival rates, potentially offering a significant advancement in immunotherapy for colorectal cancer patients.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.

More about Imugene Limited

Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies that activate the immune system to treat and eradicate tumors. The company utilizes unique platform technologies to harness the body’s immune response against tumors, aiming for effects comparable to or greater than traditional monoclonal antibody therapies. Its pipeline includes an allogeneic cell therapy CAR T drug, azer-cel, targeting CD19 for the treatment of blood cancers.

YTD Price Performance: -59.46%

Average Trading Volume: 23,744,089

Technical Sentiment Signal: Sell

Current Market Cap: A$112M

See more insights into IMU stock on TipRanks’ Stock Analysis page.